Last $5.26 USD
Change Today +0.03 / 0.57%
Volume 138.3K
NBS On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 09/23/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Alan G. Harris M.D., Ph.D., FACP FRCP

Vice President of Regenerative Medicine, Drug Development & Regulatory Affairs, Neostem, Inc.
AgeTotal Calculated CompensationThis person is connected to 5 board members in 1 different organizations across 4 different industries.

See Board Relationships
63--

Background*

Dr. Alan G. Harris, M.D. Ph.D. FACP FRCP has been Vice President of Regenerative Medicine Drug evelopment and Regulatory Affairs at Neostem Inc. since July 2009. Dr. Harris serves as an Officer of Ophthalmic Imaging Systems Inc. Dr. Harris served as Chief Medical Officer of Immune Pharmaceuticals Corp. since September 2011. Dr. Harris was responsible to develop Bertilimumab, company's phase II ready fully human monoclonal antibody for Crohn's Disease and lcerative Colitis ...

Read Full Background

Corporate Headquarters*

420 Lexington Avenue
New York, New York 10170

United States

Phone: 212-584-4180
Fax: 646-514-7787

Board Members Memberships*

There is no Board Members Memberships data available.

Education*

PhD
Erasmus University
MD
Université de Strasbourg

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

There is no Total Compensation data available.
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NBS:US $5.26 USD +0.03

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Gil Van Bokkelen Ph.D.Co-Founder, Chairman and Chief Executive Officer
Athersys, Inc.
$568.8K
Michael D. West Ph.D.Chief Executive Officer, President and Director
BioTime, Inc.
$745.3K
Marc H. Hedrick M.D.Chief Executive Officer, President, Director and Member of Executive Committee
Cytori Therapeutics, Inc.
$406.6K
Martin P. Rosendale Chief Executive Officer and Director
Cytomedix, Inc.
$467.3K
Zami Aberman Executive Chairman and Chief Executive Officer
Pluristem Therapeutics, Inc.
$503.7K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOSTEM INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.